» Articles » PMID: 28098738

SUBRETINAL CELL-BASED THERAPY: An Analysis of Surgical Variables to Increase Cell Survival

Overview
Journal Retina
Date 2017 Jan 19
PMID 28098738
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To develop a novel surgical approach to provide consistent delivery of cell suspension into the subretinal space without cell leakage into the vitreous.

Methods: Cell viability was assessed following mock injections to determine the optimal size cannula for delivery of the cells. A pars plana without vitrectomy approach was used to create a subretinal bleb with balanced salt solution using a 41-gauge cannula. GFP-labeled retinal pigment epithelium cells were injected through transretinal (n = 8) and transscleral (n = 16) injection approaches. Optical coherence tomography, fundus photography and autofluorescence, and histological analysis were used to evaluate surgical success.

Results: The 30-gauge cannula yielded the highest recovery of cells with highest viability. The transretinal approach consistently resulted in transplanted cells in the vitreous, with some cells coming to rest on the inner limiting membrane. Conversely, the transscleral approach resulted in transplantation of cells into the subretinal space in 100% of cases. Histological analysis confirmed these results.

Conclusion: We have developed a novel surgical approach that resulted in encapsulation of transplanted cells into the subretinal space with a 100% success rate. This approach will provide a useful tool for further cell transplantation study and may provide an approach for clinical application of delivering cells to the subretinal space.

Citing Articles

Towards Stem/Progenitor Cell-Based Therapies for Retinal Degeneration.

Liu H, Lu S, Chen M, Gao N, Yang Y, Hu H Stem Cell Rev Rep. 2024; 20(6):1459-1479.

PMID: 38809490 DOI: 10.1007/s12015-024-10740-4.


Backflow reduction in local injection therapy with gelatin formulations.

Kotani K, Ngako Kadji F, Mandai Y, Hiraoka Y Drug Deliv. 2024; 31(1):2329100.

PMID: 38515401 PMC: 10962293. DOI: 10.1080/10717544.2024.2329100.


Stem cell therapy in retinal diseases.

Voisin A, Penaguin A, Gaillard A, Leveziel N Neural Regen Res. 2022; 18(7):1478-1485.

PMID: 36571345 PMC: 10075102. DOI: 10.4103/1673-5374.361537.


An improved protocol for generation and characterization of human-induced pluripotent stem cell-derived retinal pigment epithelium cells.

Surendran H, Soundararajan L, Reddy K V, Subramani J, Stoddard J, Reynaga R STAR Protoc. 2022; 3(4):101803.

PMID: 36386870 PMC: 9641055. DOI: 10.1016/j.xpro.2022.101803.


CRISPR/Cas9 editing of the MYO7A gene in rhesus macaque embryos to generate a primate model of Usher syndrome type 1B.

Ryu J, Statz J, Chan W, Burch F, Brigande J, Kempton B Sci Rep. 2022; 12(1):10036.

PMID: 35710827 PMC: 9203743. DOI: 10.1038/s41598-022-13689-x.


References
1.
Kundu J, Michaelson A, Baranov P, Young M, Carrier R . Approaches to cell delivery: substrates and scaffolds for cell therapy. Dev Ophthalmol. 2014; 53:143-54. DOI: 10.1159/000357369. View

2.
Schwartz S, Regillo C, Lam B, Eliott D, Rosenfeld P, Gregori N . Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2014; 385(9967):509-16. DOI: 10.1016/S0140-6736(14)61376-3. View

3.
Xian B, Huang B . The immune response of stem cells in subretinal transplantation. Stem Cell Res Ther. 2015; 6:161. PMC: 4568575. DOI: 10.1186/s13287-015-0167-1. View